Description
Operator of a drug research and development company designed to offer treatment for cancer disease to patients. The company offers re-profiling drugs for treating additional forms of cancer, enabling cancer patients to begin their treatment and get successful cures for cancer.
Contact Information
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
1. Early Stage VC | Completed | Startup |
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20210015797-A1 | Treatment for inflammatory disease | Active | 19-Dec-2017 | 00000000000 | |
US-11504356-B2 | Treatment for inflammatory disease | Active | 19-Dec-2017 | 00000000000 | 0 |
AU-2018387255-A1 | Treatment for inflammatory disease | Pending | 19-Dec-2017 | 00000000000 | |
CA-3086101-A1 | Treatment for inflammatory disease | Pending | 19-Dec-2017 | 00000000000 | |
EP-3727373-A2 | Treatment for inflammatory disease | Pending | 19-Dec-2017 | A61K31/4184 |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Sven Mårten Fryknäs | Co-Founder, Chief Executive Officer, Managing Director & Board Member | ||
Angelica Loskog | President & Chairman |
Name | Representing | Role | Since |
---|---|---|---|
Angelica Loskog | Self | President & Chairman | 000 0000 |
Hans Nygren | Self | Board Member | 000 0000 |
Rolf Larsson | Self | Board Member | 000 0000 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Nxt2b | Venture Capital | Minority | 000 0000 | 000000 0 |